December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

140.30 +0.93 (+0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
72 73 Next >
News headline image
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst ↗
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
News headline image
The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts ↗
 
Via Benzinga
News headline image
What the Options Market Tells Us About Gilead Sciences ↗
 
Via Benzinga
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today ↗
 
Via Benzinga
News headline image
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? ↗
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
News headline image
Undervalued Icons: 3 Household Names Trading at Steep Discounts ↗
Three of Wall Street's undervalued stocks could provide a unique blend of stability and long-term growth potential. 
Via InvestorPlace
News headline image
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
News headline image
Why the dividend investor may take a look at NASDAQ:GILD. ↗
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
News headline image
Better Growth Play: Merck or The Vanguard Growth Index Fund? ↗
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today ↗
 
Via Benzinga
News headline image
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq? ↗
Dividend stocks can be a smart way to ride out market volatility. 
Via The Motley Fool
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
3 Stocks at 52-Week Lows Poised for a Powerful Rebound ↗
Starbucks, Gilead, and Vale are three stocks at 52-week lows that show signs of recovery potential and long-term growth prospects. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip? ↗
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window. 
Via Benzinga
News headline image
3 No-Brainer Dividend Stocks to Buy in April ↗
Income investors will find a lot to like about these stocks. 
Via The Motley Fool
News headline image
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows ↗
All of these stocks pay generous dividends that income investors will appreciate. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains 
Via MarketBeat
Topics ETFs
News headline image
5 Healthcare Stocks to Buy for 2024 ↗
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst ↗
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
Via Benzinga
News headline image
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy? ↗
Over the past twelve months, a number of big-name companies have been near or below their 52-week low price. Each week we’ll take a look at some of the biggest names currently close to their 52-week... 
Via Talk Markets
News headline image
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why ↗
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered... 
Via Benzinga
News headline image
Why Is Xilio Therapeutics (XLO) Stock up 168% Today? ↗
Xilio Therapeutics stock is heading higher on Thursday with heavy trading of XLO shares after announcing a deal with Gilead. 
Via InvestorPlace
News headline image
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.